Relationship between pre-pregnancy body-mass-index and gestational age-specific risk of stillbirth and perinatal death in women with chronic hypertension.

Background: Obesity is a risk factor for stillbirth and perinatal death and is often accompanied by chronic hypertension; however, there are few studies on the relationship between pre-pregnancy BMI and gestational age (GA)-specific rates of stillbirth and perinatal death in women with chronic hypertension.

Objective: The objective of this study was to examine the relationship between pre-pregnancy BMI and GA-specific risk of stillbirth and perinatal death in the presence/absence of chronic hypertension.

Methods: This was a retrospective cohort study of all singleton births in the United States in 2016-17.

Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response.

The Risk for Glucose Intolerance after Gestational Diabetes Mellitus since the Introduction of the IADPSG Criteria: A Systematic Review and Meta-Analysis.

The aim of the study was to assess the postpartum risk for glucose intolerance since the introduction of the 'International Association of Diabetes and Pregnancy Study Groups' (IADPSG) criteria for gestational diabetes mellitus (GDM). Studies published since 2010 were included, which evaluated the risk for type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), and cardiovascular (CV) events in women with previous GDM compared to normal glucose tolerant women. We included forty-three studies, evaluating 4,923,571 pregnant women of which 5.

Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.

Background: Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic diseases in the world and an important cause of premature cardiovascular (CV) disease. The purpose of this study was to characterize the clinical features, current treatment patterns, and CV outcomes of patients with HeFH in British Columbia, Canada.

Methods: We conducted a longitudinal observational study of patients with HeFH attending a specialized lipid clinic.